Somatostatin News and Research RSS Feed - Somatostatin News and Research

Molecular imaging technique could help optimize radiotherapy dose to combat NETs

Molecular imaging technique could help optimize radiotherapy dose to combat NETs

Aggressive neuroendocrine cancer is something of a dark horse--a rare, elusive and persevering force linked to discouraging long-term survival rates. [More]
Genetic blood test can help predict patient’s respone to neuroendocrine cancer therapy

Genetic blood test can help predict patient’s respone to neuroendocrine cancer therapy

Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor long-term survival. According to research presented at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, an investigative blood test could predict how patients will respond to peptide receptor radionuclide therapy (PRRT) before they commit to a course of treatment. [More]
Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs). The data will be presented Monday, June 6, during the American Society of Clinical Oncology Annual Meeting in Chicago. [More]
Advanced imaging kit Netspot gets FDA approval to detect rare neuroendocrine tumors

Advanced imaging kit Netspot gets FDA approval to detect rare neuroendocrine tumors

The U.S. Food and Drug Administration today approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging. [More]
Altered circadian somatostatin expression linked to bipolar disorder

Altered circadian somatostatin expression linked to bipolar disorder

Results of the first study of its kind to link abnormalities in circadian rhythms to changes in specific neurotransmitters in people with bipolar disorder will be published this week in the journal Biological Psychiatry. [More]
Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. [More]
Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

Lexicon Pharmaceuticals, Inc. announced today that top-line data from its TELECAST Phase 3 study showed results of telotristat etiprate in treating carcinoid syndrome in cancer patients with metastatic neuroendocrine tumors consistent with the clinical benefit observed in its pivotal TELESTAR study. [More]
Study demonstrates efficacy of everolimus in treating nonfunctional neuroendocrine tumours of the lung

Study demonstrates efficacy of everolimus in treating nonfunctional neuroendocrine tumours of the lung

The results of the international, multicenter, Phase 3 RADIANT-4 study clearly demonstrate the efficacy of the agent everolimus in treating nonfunctional neuroendocrine tumours of lung or gastrointestinal origin. [More]
Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Lexicon Pharmaceuticals, Inc.'s telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study presented at the 2015 Neuroendocrine Tumor Society Annual Symposium in Austin, Texas. [More]
Researchers find how different neurons work together to reduce responses to frequent sounds

Researchers find how different neurons work together to reduce responses to frequent sounds

Being able to understand speech is essential to our evolution as humans. Hearing lets us perceive the same word even when spoken at different speeds or pitches, and also gives us extra sensitivity to unexpected sounds. Now, new studies from the Perelman School of Medicine at the University of Pennsylvania clarify how these two crucial features of audition are managed by the brain. [More]
Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

Positive progression-free survival results from the RADIANT-4 and NETTER-1 trials extend the armamentarium for physicians treating patients with neuroendocrine tumours. [More]
FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Chiasma, Inc., a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly. [More]
Understanding crosstalk between cells in the pancreas can help treat diabetes

Understanding crosstalk between cells in the pancreas can help treat diabetes

Sometimes, listening in on a conversation can tell you a lot. For Mark Huising, an assistant professor in the Department of Neurobiology, Physiology and Behavior at the UC Davis College of Biological Sciences, that crosstalk is between the cells that control your body's response to sugar, and understanding the conversation can help us understand, and perhaps ultimately treat, diabetes. [More]
Chiasma closes $70 million Series E financing round

Chiasma closes $70 million Series E financing round

Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the closing of a $70 million Series E financing round. [More]
Carnegie Mellon study identifies intermediary neuron system that acts as synaptic cloaking device

Carnegie Mellon study identifies intermediary neuron system that acts as synaptic cloaking device

Neuroscientists believe that the connectome, a map of each and every connection between the millions of neurons in the brain, will provide a blueprint that will allow them to link brain anatomy to brain function. But a new study from Carnegie Mellon University has found that a specific type of neuron might be thwarting their efforts at mapping the connectome by temporarily cloaking the synapses that link a wide field of neurons. [More]
Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma Inc., a U.S. privately-held biopharma company, announced today that results from a multicenter Phase III study of the investigational new drug, octreotide capsules, were published online for early release on Feb. 9, ahead of print, by the Journal of Clinical Endocrinology & Metabolism. [More]
Novel technique could help identify cancerous tissue during brain tumor surgery

Novel technique could help identify cancerous tissue during brain tumor surgery

A novel radioguided surgery technique could quickly and effectively identify residual cancer cells during brain tumor surgery, with low radiation exposure for both patients and surgeons. The study, featured in the January 2015 issue of the Journal of Nuclear Medicine, reports that Y-90 DOTATOC, a beta-minus-emitting tracer, can effectively delineate the margins of meningiomas and high-grade gliomas. [More]
Ipsen's Somatuline Depot Injection 120 mg receives FDA approval for treatment of GEP-NETs

Ipsen's Somatuline Depot Injection 120 mg receives FDA approval for treatment of GEP-NETs

Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, today announced that Somatuline Depot (lanreotide) Injection 120 mg (referred to as Somatuline) was approved by the U.S. Food and Drug Administration for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic disease to improve progression-free survival (PFS). [More]
Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. [More]
Researchers identify important neural mechanism responsible for certain chronic pain disorders

Researchers identify important neural mechanism responsible for certain chronic pain disorders

Pain typically has a clear cause-but not always. When a person touches something hot or bumps into a sharp object, it's no surprise that it hurts. But for people with certain chronic pain disorders, including fibromyalgia and phantom limb pain, a gentle caress can result in agony. [More]
Advertisement
Advertisement